GOLD REPORTING: How to Sell Gold Without Paying Taxes?

Below bullion buyers can learn about current US based bullion dealer IRS reporting rules. Not only when selling bullion but also when buying bullion. As well too, get a general understanding as to what federal US tax laws of the land, mean for silver and gold taxes and current US Congressional efforts ongoing to change them. First thing. I’m no ...

Read More »

Developer of Nitric Oxide Delivery Devices Rebrands to Focus on Leading Advancements [NUMD]

This Utah-based company rolled out an online campaign that highlights its strategic repositioning. Nu-Med Plus Inc. (NUMD:OTC.MKTS) launched a rebrand that distinguishes it as an industry leader that is “reinventing the healing power of nitric oxide delivery,” according to the company. The mission of this medical device company is to “explore medical applications of newly developed nitric oxide technologies,” the ...

Read More »

Developer of Nitric Oxide Delivery Devices Rebrands to Focus on Leading Advancements [NUMD]

This Utah-based company rolled out an online campaign that highlights its strategic repositioning. Nu-Med Plus Inc. (NUMD:OTC.MKTS) launched a rebrand that distinguishes it as an industry leader that is “reinventing the healing power of nitric oxide delivery,” according to the company. The mission of this medical device company is to “explore medical applications of newly developed nitric oxide technologies,” the ...

Read More »

50% Stock Crash Coming | Michael Pento

Podcast: Play in new window | Download Subscribe: Apple Podcasts | Android | Email | Stitcher | Michael Pento tells Silver Doctors beginning now and going into 2019, the stock market will be moving quite differently then the last couple years… Michael Pento of Pento Portfolio Strategies interviewed by Elijah Johnson of Silver Doctors The U.S. stock market is 140% ...

Read More »

Texas Heart Takes to the CoreoGraft

Daniel Carlson of Tailwinds Research profiles Hancock Jaffe Laboratories, which is partnering with the Texas Heart Institute to further develop an innovative graft designed for use in coronary bypass surgery. This week Hancock Jaffe Laboratories Inc. (HJLI:NASDAQ) announced a partnership with the Texas Heart Institute, a world-renowned leader in cardiovascular disease. This partnership, which is for the development of their ...

Read More »

This Biotech Is Harnessing the Microbiomes Therapeutic Potential

A LifeSci Capital report presented a handful of key points about the firm. In a Oct. 5 research note, analyst Patrick Dolezal reported that LifeSci Capital initiated coverage on 4D Pharma Plc (DDDD:LSE), a United Kingdom-based developer of biotherapeutics. Dolezal highlighted five of the company’s advantages: 1. 4D Pharma’s methodology differs from that of other microbiome companies. Whereas others typically ...

Read More »

This Biotech Is Harnessing the Microbiomes Therapeutic Potential

A LifeSci Capital report presented a handful of key points about the firm. In a Oct. 5 research note, analyst Patrick Dolezal reported that LifeSci Capital initiated coverage on 4D Pharma Plc (DDDD:LSE), a United Kingdom-based developer of biotherapeutics. Dolezal highlighted five of the company’s advantages: 1. 4D Pharma’s methodology differs from that of other microbiome companies. Whereas others typically ...

Read More »

FDA Approves Biopharmas Drug with $1.75 Billion Peak Sales Potential

An H.C. Wainwright & Co. report covered the greenlighting of two therapeutics developed by this firm, whose stock, according to the analyst, has more than fivebagger return potential. In an Oct. 3 research note, analyst Ed Arce reported the FDA approved two of Paratek Pharmaceuticals Inc.’s (PRTK:NASDAQ) therapies, Seysara and Nusyra, on Oct. 1 and Oct. 2, respectively. As expected, ...

Read More »

The Price Action In Gold Does Not Make Sense

Is this the start of just a corrective rally in gold, or is this actually a gold break-out? Here are some price levels to be watching to answer that question… by Avi Gilburt of Elliott Wave Trader I have been hearing for years how gold is manipulated to go down, and is expected to rise when allowed to trade freely. ...

Read More »

FDA Approves Biopharmas Drug with $1.75 Billion Peak Sales Potential

An H.C. Wainwright & Co. report covered the greenlighting of two therapeutics developed by this firm, whose stock, according to the analyst, has more than fivebagger return potential. In an Oct. 3 research note, analyst Ed Arce reported the FDA approved two of Paratek Pharmaceuticals Inc.’s (PRTK:NASDAQ) therapies, Seysara and Nusyra, on Oct. 1 and Oct. 2, respectively. As expected, ...

Read More »